PE20211636A1 - Dinucleotidos ciclicos como agonistas de sting - Google Patents

Dinucleotidos ciclicos como agonistas de sting

Info

Publication number
PE20211636A1
PE20211636A1 PE2021000048A PE2021000048A PE20211636A1 PE 20211636 A1 PE20211636 A1 PE 20211636A1 PE 2021000048 A PE2021000048 A PE 2021000048A PE 2021000048 A PE2021000048 A PE 2021000048A PE 20211636 A1 PE20211636 A1 PE 20211636A1
Authority
PE
Peru
Prior art keywords
cancer
sting
sting agonists
cyclic dinucleotides
compounds
Prior art date
Application number
PE2021000048A
Other languages
English (en)
Inventor
Stuart Emanuel
Mark Richter
Peter J Connolly
James P Edwards
Guangyi Wang
Santhosh Kumar Thatikonda
Leonid Beigelman
Gilles Bignan
Marcel Viellevoye
Johannes Wilhelmus J F Thuring
Wim Bert Griet Schepens
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of PE20211636A1 publication Critical patent/PE20211636A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
    • C07H19/207—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids the phosphoric or polyphosphoric acids being esterified by a further hydroxylic compound, e.g. flavine adenine dinucleotide or nicotinamide-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7084—Compounds having two nucleosides or nucleotides, e.g. nicotinamide-adenine dinucleotide, flavine-adenine dinucleotide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/23—Heterocyclic radicals containing two or more heterocyclic rings condensed among themselves or condensed with a common carbocyclic ring system, not provided for in groups C07H19/14 - C07H19/22
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/04—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with deoxyribosyl as saccharide radical

Abstract

Esta referido a compuestos de Formula I, en donde: R1, R2 son H, OH, F, alcoxi, entre otros; R1', R2' son H, F, OH; R3 es H, F, CH3, CH2F; X1, X2 son O, S, CH2; B1, B2 son las formulas b1, b2, b3, b4, b5, b6, b7, b8, b9, b10, b11, b12, b13, b14, b15, b16, b17, b18, b19, b20, b21, b22, b23, b24, b25, b26, b27, b28, b29, o b30; M, M1 son como se indica al final; L, L1 son CH2, CH2-CH2; Z, Z1 son O, NH; Y, Y1 estan ausentes o son O, NH. Estos compuestos son agonistas del estimulador de genes de interferon (STING, por sus siglas en ingles) y son utiles para el tratamiento de trastornos en los que se afecta la modulacion de la proteina STING como melanoma, cancer de colon, cancer de mama, cancer de prostata, cancer de pulmon, fibrosarcoma, y para la terapia antiviral.
PE2021000048A 2018-07-17 2019-07-16 Dinucleotidos ciclicos como agonistas de sting PE20211636A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862699001P 2018-07-17 2018-07-17
PCT/IB2019/056075 WO2020016782A1 (en) 2018-07-17 2019-07-16 Cyclic dinucleotides as sting agonists

Publications (1)

Publication Number Publication Date
PE20211636A1 true PE20211636A1 (es) 2021-08-24

Family

ID=67999987

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2021000048A PE20211636A1 (es) 2018-07-17 2019-07-16 Dinucleotidos ciclicos como agonistas de sting

Country Status (20)

Country Link
US (2) US11597746B2 (es)
EP (1) EP3823976A1 (es)
JP (1) JP2021531277A (es)
KR (1) KR20210033026A (es)
CN (1) CN112424212A (es)
AR (1) AR122240A1 (es)
AU (1) AU2019304230B2 (es)
BR (1) BR112021000693A2 (es)
CA (1) CA3106602A1 (es)
EA (1) EA202190298A1 (es)
EC (1) ECSP21003171A (es)
IL (1) IL280105A (es)
MA (1) MA53178A (es)
MX (1) MX2021000625A (es)
PE (1) PE20211636A1 (es)
PH (1) PH12020552172A1 (es)
SG (1) SG11202012624RA (es)
TW (1) TW202030199A (es)
UY (1) UY38304A (es)
WO (1) WO2020016782A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3724205B1 (en) * 2017-12-15 2022-06-22 Janssen Biotech, Inc. Cyclic dinucleotides as sting agonists
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸
EP4134098A4 (en) 2020-04-10 2024-05-15 Ono Pharmaceutical Co CANCER THERAPY METHODS

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA52157A (fr) * 2015-12-03 2021-02-17 Glaxosmithkline Ip Dev Ltd Dinucléotides cycliques de purine utilisés comme modulateurs de sting
CN109451740B (zh) * 2016-01-11 2022-09-02 先天肿瘤免疫公司 用于治疗与sting活性相关的病症诸如癌症的环状二核苷酸
WO2017123657A1 (en) * 2016-01-11 2017-07-20 Gary Glick Cyclic dinucleotides for treating conditions associated with sting activity such as cancer
IL280430B2 (en) 2016-03-18 2023-11-01 Univ Texas Cyclic dinucleotide compounds and methods of use
EP3481402A4 (en) * 2016-07-06 2020-01-22 Sperovie Biosciences, Inc. CONNECTIONS, COMPOSITIONS AND METHODS FOR TREATING A DISEASE
WO2018045204A1 (en) 2016-08-31 2018-03-08 Ifm Therapeutics, Inc Cyclic dinucleotide analogs for treating conditions associated with sting (stimulator of interferon genes) activity
JOP20170188A1 (ar) * 2016-11-25 2019-01-30 Janssen Biotech Inc ثنائي النوكليوتيدات الحلقية كمنبهات ستينغ (sting)
TW202030199A (zh) * 2018-07-17 2020-08-16 美商健生生物科技公司 作為ｓｔｉｎｇ促效劑之環狀二核苷酸

Also Published As

Publication number Publication date
ECSP21003171A (es) 2021-02-26
EA202190298A1 (ru) 2021-04-16
KR20210033026A (ko) 2021-03-25
CA3106602A1 (en) 2020-01-23
CN112424212A (zh) 2021-02-26
US20210277046A1 (en) 2021-09-09
SG11202012624RA (en) 2021-02-25
WO2020016782A1 (en) 2020-01-23
IL280105A (en) 2021-03-01
AU2019304230A1 (en) 2021-01-14
MX2021000625A (es) 2021-03-25
AU2019304230B2 (en) 2023-08-31
UY38304A (es) 2020-01-31
PH12020552172A1 (en) 2021-06-07
AR122240A1 (es) 2022-08-31
US20230287034A1 (en) 2023-09-14
TW202030199A (zh) 2020-08-16
US11597746B2 (en) 2023-03-07
MA53178A (fr) 2021-05-26
EP3823976A1 (en) 2021-05-26
BR112021000693A2 (pt) 2021-04-13
JP2021531277A (ja) 2021-11-18

Similar Documents

Publication Publication Date Title
PE20211636A1 (es) Dinucleotidos ciclicos como agonistas de sting
CL2019003793A1 (es) Moduladores de moléculas pequeñas de sting humana.
PE20151982A1 (es) Derivados de bencimidazolona como inhibidores del bromodominio
PE20211812A1 (es) COMPUESTOS 1H-PYRAZOLO [4,3-d]PIRIMIDINA COMO AGONISTAS DEL RECEPTOR 7 TIPO TOLL (TLR7) Y METODOS Y USOS DE LOS MISMOS
DOP2022000038A (es) Nanopartícula lipídicas mejoradas para el suministro de ácidos nucleicos
PE20181297A1 (es) Dinucleotidos de purino ciclico como moduladores de sting
SA519401435B1 (ar) مركبات حلقية ثنائية النيوكليوتيد
EA200701094A1 (ru) Усовершенствованное лечение рака с применением агонистов tlr3
UY36293A (es) Nuevos compuestos como inhibidores de ret (reorganizado durante la transfección)
MX2021011209A (es) Novedosos inhibidores de molécula pequeña de factores de transcripción tead.
PH12015502018A1 (en) 3-pyrimidin-4-yl-oxazolidin-2-ones as inhibitors of mutant idh
CL2020001945A1 (es) Compuestos.
AR066849A1 (es) Polipeptidos, dominios variables de anticuerpos y antagonistas del factor de crecimiento endotelial vascular (vegf)
UY35268A (es) Modulador del receptor de andrógeno 4-[7-(6-ciano-5-trifluorometilpiridin-3-il)-8-oxo-6-tioxo-5,7-diazaespiro[3.4]oct-5-il]-2-fluoro-N-metilbenzamida y sus usos
PE20210412A1 (es) Moduladores de sting (estimulador de genes de interferon) a base de ciclopentano
CO2021006672A2 (es) Moduladores de nlrp3
ES2721639T3 (es) Método para el diagnóstico, pronóstico y tratamiento de la metástasis de cáncer de mama
MX2022003758A (es) Composiciones para el cuidado bucal que comprenden acido beta de lupulo y aminoacido.
PH12020551994A1 (en) Tlr7 agonists
MY180502A (en) Compound of glycosaminoglycan, preparation method and use thereof
GT200200190A (es) Compuestos de benzimidazol sustituido y su utilizacion en el tratamiento del cancer
NZ745185A (en) 3-((hetero-)aryl)-8-amino-2-oxo-1,3-diaza-spiro-[4.5]-decane derivatives
PE20220425A1 (es) Derivado de 1,1-dioxido de 3-amino-4h-benzo[e][1,2,4]tiadiazina como inhibidores de mrgx2
CR9496A (es) Moduladores de androgenos
AU2021304762B2 (en) Novel polypeptide and therapeutic use thereof